ReviewACS pharmacology & translational science2025
Impact of Symptomatic Slow-Acting Drugs on Inflammatory Pathways in Osteoarthritis: Therapeutic Advances and Future Challenges.
Review in ACS pharmacology & translational science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteoarthritis (OA) is a leading cause of physical disability, psychological distress, and a significant economic burden worldwide. Current treatments alleviate symptoms; however, disease progression remains largely uncontrolled, highlighting the urgent need for investigation of disease-modifying therapies. Symptomatic slow-acting drugs for osteoarthritis (SYSADOAs), such as glucosamine (GlcN), chondroitin sulfate (CS), and hyaluronic acid (HA), have gained increasing attention for their potential benefits in alleviating pain and mitigating the inflammatory and degenerative processes that characterize OA. These compounds modulate several homeostatic mechanisms, promoting anti-inflammatory, antioxidant, antiapoptotic, and anabolic countermensuring effects. Nevertheless, debates regarding their long-term efficacy and safety remain controversial, which explains why major osteoarthritis societies do not provide the same recommendations for the pharmacological treatment of OA. In this context, this review critically evaluates the current evidence surrounding HA, GlcN, and CS, highlighting their safety, mechanisms of action, and promising therapeutic perspectives for modifying the natural course of knee, hand, and hip OA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.